Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: PG stock price vs MRNA: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at MRNA's multiple
Needs MRNA P/E.
Implied fair value · at PG's multiple
Needs Annual EPS is negative, PG P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Nine period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
The Procter & Gamble Company · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Moderna, Inc. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
COLGATE PALMOLIVE CO
PG vs CL
KIMBERLY CLARK CORP
PG vs KMB
CHURCH & DWIGHT CO INC /DE/
PG vs CHD
CLOROX CO /DE/
PG vs CLX
Johnson & Johnson
PG vs JNJ
PFIZER INC
PG vs PFE
GILEAD SCIENCES, INC.
PG vs GILD
AMGEN INC
PG vs AMGN
NOVAVAX INC
PG vs NVAX
VERTEX PHARMACEUTICALS INC / MA
PG vs VRTX
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe PG can sustain its premium profitability and cash generation despite only 0.3% revenue growth, then hold or accumulate selectively; otherwise, trim exposure because the current price of $140.06 sits well above the DCF range of $63.47-$85.86 and already reflects much of PG’s quality premium.
On the provided P/S basis, PG’s current price of $140.06 is well below MRNA-implied $336.96, implying 140.6% upside, but that comparison is distorted because MRNA has much smaller revenue and negative earnings. PG also sits above the upper end of its DCF range and modestly below the top of its historical band, suggesting the stock is closer to fair-to-rich on intrinsic measures than MRNA-implied price indicates.
Supporting Metrics
